The Rheumatology Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Rheumatology Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report
According to The Business Research Company’s Rheumatology Therapeutics Global Market Report 2024, The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $51.42 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to the shift towards personalized medicine approaches, rising adoption of biosimilars in rheumatology, increasing investment in research and development, integration of digital health technologies, and regulatory approvals for novel therapies. Major trends in the forecast period include growth in telemedicine and remote monitoring solutions, expansion of targeted therapies for specific rheumatic conditions, emphasis on patient-centric care models, expansion of biologic treatments beyond monoclonal antibodies, and adoption of value-based pricing models.
The rising prevalence of autoimmune diseases is expected to propel the growth of the rheumatology therapeutics market going forward. An autoimmune disease is a condition where the immune system mistakenly attacks and damages the body’s tissues. The prevalence of autoimmune diseases is growing due to a combination of genetic, environmental, and lifestyle factors, including increased awareness and improved diagnostic capabilities. Rheumatology therapeutics are required for autoimmune diseases to manage inflammation, alleviate symptoms, and prevent joint and tissue damage caused by the immune system attacking the body. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 514,000 people in Australia, or 2.0% of the population, were estimated to be living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the rheumatology therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications
Major companies operating in the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, to enhance treatment efficacy and patient convenience. An intravenous (IV) formulation refers to a medication or substance that is administered directly into a vein through a needle or catheter. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This form of Cosentyx is uniquely approved to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It works by specifically targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-α) IV treatment available for these conditions.
The rheumatology therapeutics market report table of contents includes:
1. Executive Summary
2. Rheumatology Therapeutics Market Characteristics
3. Rheumatology Therapeutics Market Trends And Strategies
4. Rheumatology Therapeutics Market – Macro Economic Scenario
5. Global Rheumatology Therapeutics Market Size and Growth
………..
32. Global Rheumatology Therapeutics Market Competitive Benchmarking
33. Global Rheumatology Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Rheumatology Therapeutics Market
35. Rheumatology Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
